Trials / Terminated
TerminatedNCT05208177
A Study of SHR-1802 in Patients With Advanced Solid Tumor
A Phase Ⅰb/Ⅱ Dose-exploration and Efficacy-expansion Study of SHR-1802 Combined With Camrelizumab for Injection and Famitinib Malate Capsules for the Treatment of Advanced Solid Tumor
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety and tolerability of SHR-1802 combined with camrelizumab and famitinib in subjects with advanced solid tumor and to determine the dose-limiting toxicity (DLT)，recommended phase II dose (RP2D) and assess objective response rate (ORR) assessed by the investigator based on RECIST v1.1 criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1802＋camrelizumab + famitinib | SHR-1802 for injection，q3w； Camrelizumab for injection, q3w; Famitinib malate capsules, qd. |
Timeline
- Start date
- 2022-04-22
- Primary completion
- 2023-08-18
- Completion
- 2023-08-18
- First posted
- 2022-01-26
- Last updated
- 2025-08-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05208177. Inclusion in this directory is not an endorsement.